The EntroGen NGS Targeted Hotspot Panel is a comprehensive assay that detects clinically relevant mutations in solid tumors using next-generation sequencing, compatible with fresh frozen and FFPE samples. It offers high sensitivity, low DNA input, and the ability to batch up to 12 samples in a single run, making it ideal for labs with limited sample volumes.

EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.

SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.

SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC

PANA RealTyper^TM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition